These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38246222)

  • 1. Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities.
    Steiner S; Pliego-Mendieta A; Haberecker M; Hussung S; Kollár A; Fritsch R; Arnold F; Lenggenhager D; Planas-Paz L; Pauli C
    Cancer Lett; 2024 Mar; 584():216650. PubMed ID: 38246222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organoid models for translational pancreatic cancer research.
    Tiriac H; Plenker D; Baker LA; Tuveson DA
    Curr Opin Genet Dev; 2019 Feb; 54():7-11. PubMed ID: 30844513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
    Farshadi EA; Chang J; Sampadi B; Doukas M; Van 't Land F; van der Sijde F; Vietsch EE; Pothof J; Koerkamp BG; van Eijck CHJ
    Clin Cancer Res; 2021 Dec; 27(23):6602-6612. PubMed ID: 34580113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
    Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
    Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.
    Xavier CB; Marchetti KR; Castria TB; Jardim DLF; Fernandes GS
    J Gastrointest Cancer; 2021 Mar; 52(1):374-380. PubMed ID: 33225411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
    Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
    Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
    Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
    Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
    Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
    Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
    Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
    United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biological underpinnings of therapeutic resistance in pancreatic cancer.
    Beatty GL; Werba G; Lyssiotis CA; Simeone DM
    Genes Dev; 2021 Jul; 35(13-14):940-962. PubMed ID: 34117095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.
    Huang L; Holtzinger A; Jagan I; BeGora M; Lohse I; Ngai N; Nostro C; Wang R; Muthuswamy LB; Crawford HC; Arrowsmith C; Kalloger SE; Renouf DJ; Connor AA; Cleary S; Schaeffer DF; Roehrl M; Tsao MS; Gallinger S; Keller G; Muthuswamy SK
    Nat Med; 2015 Nov; 21(11):1364-71. PubMed ID: 26501191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients.
    Sandhya S; Hogenson TL; Fernandez-Zapico ME
    EMBO Mol Med; 2022 Apr; 14(4):e15707. PubMed ID: 35285156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
    Zhang Y; Houchen CW; Li M
    Clin Cancer Res; 2022 Aug; 28(15):3176-3178. PubMed ID: 35617521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
    Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
    Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Organoids from pancreatic ductal adenocarcinoma].
    Dusetti N; Iovanna J
    Med Sci (Paris); 2020 Jan; 36(1):57-62. PubMed ID: 32014099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
    Pham NA; Radulovich N; Ibrahimov E; Martins-Filho SN; Li Q; Pintilie M; Weiss J; Raghavan V; Cabanero M; Denroche RE; Wilson JM; Metran-Nascente C; Borgida A; Hutchinson S; Dodd A; Begora M; Chadwick D; Serra S; Knox JJ; Gallinger S; Hedley DW; Muthuswamy L; Tsao MS
    Sci Rep; 2021 May; 11(1):10619. PubMed ID: 34011980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.
    Parasido E; Avetian GS; Naeem A; Graham G; Pishvaian M; Glasgow E; Mudambi S; Lee Y; Ihemelandu C; Choudhry M; Peran I; Banerjee PP; Avantaggiati ML; Bryant K; Baldelli E; Pierobon M; Liotta L; Petricoin E; Fricke ST; Sebastian A; Cozzitorto J; Loots GG; Kumar D; Byers S; Londin E; DiFeo A; Narla G; Winter J; Brody JR; Rodriguez O; Albanese C
    Mol Cancer Res; 2019 Sep; 17(9):1815-1827. PubMed ID: 31164413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.
    Ponz-Sarvise M; Corbo V; Tiriac H; Engle DD; Frese KK; Oni TE; Hwang CI; Öhlund D; Chio IIC; Baker LA; Filippini D; Wright K; Bapiro TE; Huang P; Smith P; Yu KH; Jodrell DI; Park Y; Tuveson DA
    Clin Cancer Res; 2019 Nov; 25(22):6742-6755. PubMed ID: 31492749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
    Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
    EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.